Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide

被引:71
作者
Bidstrup, TB
Stilling, N
Damkier, P
Scharling, B
Thomsen, MS
Brosen, K
机构
[1] Univ So Denmark, DK-5000 Odense C, Denmark
[2] Odense Univ Hosp, Dept KKA, DK-5000 Odense, Denmark
[3] Novo Nordisk AS, DK-2820 Gentofte, Denmark
[4] Prosid Ltd, Oxford, England
关键词
repaglinide; rifampicin; interaction;
D O I
10.1007/s00228-004-0746-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective. To investigate if rifampicin is both an inducer and an inhibitor of repaglinide metabolism, it was determined whether the timing of rifampicin co-administration influences the pharmacokinetics of repaglinide. Methods. Male volunteers (n=12) participated in a randomised, two-period, crossover trial evaluating the effect of multiple doses of 600 mg rifampicin once daily for 7 days on repaglinide metabolism. Subjects were, after baseline measurements of repaglinide pharmacokinetics, randomised to receive, on either day 7 or day 8 of the rifampicin administration period, a single dose of 4 mg repaglinide and vice versa in the following period. Results. When repaglinide was given, together with the last rifampicin dose, on day 7, an almost 50% reduction of the median repaglinide area under the plasma concentration-time curve (AUC) was observed. Neither the peak plasma concentration (C-max), time to reach C-max (t(max)) nor terminal half-life (t(1/2)) was statistically significantly affected. When repaglinide was given on day 8, 24 h after the last rifampicin dose, an almost 80% reduction of the median repaglinide AUC was observed. The median C-max was now statistically significantly reduced from 35 ng/ml to 7.5 ng/ml. Neither t(max) nor t(1/2) was significantly affected. Conclusion. When rifampicin and repaglinide are administered concomitantly, rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. After discontinuing rifampicin administration, while the inductive effect on CYP3A4 and probably also CYP2C8 is still present, an even more marked reduction in the plasma concentration of repaglinide was observed. Our results suggest that concomitant administration of rifampicin and repaglinide may cause a clinically relevant decrease in the glucose-lowering effect of repaglinide, in particular when rifampicin treatment is discontinued or if the drugs are not administered simultaneously or within a few hours of each other.
引用
收藏
页码:109 / 114
页数:6
相关论文
共 27 条
[1]   CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide [J].
Bidstrup, TB ;
Bjornsdottir, I ;
Sidelmann, UG ;
Thomsen, MS ;
Hansen, KT .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) :305-314
[2]   Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6 [J].
Damkier, P ;
Brosen, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :199-209
[3]   RIFAMPICIN ENHANCES ANTICANCER DRUG ACCUMULATION AND ACTIVITY IN MULTIDRUG-RESISTANT CELLS [J].
FARDEL, O ;
LECUREUR, V ;
LOYER, P ;
GUILLOUZO, A .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (09) :1255-1260
[4]   THE INCREASE IN URINARY-EXCRETION OF 6-BETA-HYDROXYCORTISOL AS A MARKER OF HUMAN HEPATIC CYTOCHROME-P450IIIA INDUCTION [J].
GED, C ;
ROUILLON, JM ;
PICHARD, L ;
COMBALBERT, J ;
BRESSOT, N ;
BORIES, P ;
MICHEL, H ;
BEAUNE, P ;
MAUREL, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (04) :373-387
[5]  
Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242
[6]   Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters [J].
Glaeser, H ;
Drescher, S ;
van der Kuip, H ;
Behrens, C ;
Geick, A ;
Burk, O ;
Dent, J ;
Somogyi, A ;
von Richter, O ;
Griese, EU ;
Eichelbaum, M ;
Fromm, MF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :131-140
[7]  
GROMADA J, 1995, DIABETOLOGIA, V38, P1025, DOI 10.1007/s001250050387
[8]   Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide [J].
Hatorp, V ;
Hansen, KT ;
Thomsen, MS .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06) :649-660
[9]  
Klose TS, 1999, J BIOCHEM MOL TOXIC, V13, P289, DOI 10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO
[10]  
2-N